Indication
For treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Upadacitinib may be used as monotherapy or in combination with methotrexate.
Medicine details
- Medicine name:
- upadacitinib (Rinvoq)
- SMC ID:
- SMC2315
- Pharmaceutical company
- AbbVie Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Publication due date:
- 08 February 2021
- SMC meeting date:
- 12 January 2021
- Patient group submission deadline:
- 30 November 2020